Cargando…
Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma
Polo-like kinase 1 (Plk1) expression is inversely correlated with survival advantages in many cancers. However, molecular mechanisms that underlie Plk1 expression are poorly understood. Here, we uncover a hypoxia-regulated mechanism of Plk1-mediated cancer metastasis and drug resistance. We demonstr...
Autores principales: | Dufies, Maeva, Verbiest, Annelies, Cooley, Lindsay S., Ndiaye, Papa Diogop, He, Xingkang, Nottet, Nicolas, Souleyreau, Wilfried, Hagege, Anais, Torrino, Stephanie, Parola, Julien, Giuliano, Sandy, Borchiellini, Delphine, Schiappa, Renaud, Mograbi, Baharia, Zucman-Rossi, Jessica, Bensalah, Karim, Ravaud, Alain, Auberger, Patrick, Bikfalvi, Andréas, Chamorey, Emmanuel, Rioux-Leclercq, Nathalie, Mazure, Nathalie M., Beuselinck, Benoit, Cao, Yihai, Bernhard, Jean Christophe, Ambrosetti, Damien, Pagès, Gilles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865059/ https://www.ncbi.nlm.nih.gov/pubmed/33547392 http://dx.doi.org/10.1038/s42003-021-01653-w |
Ejemplares similares
-
Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5
por: Giuliano, Sandy, et al.
Publicado: (2019) -
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
por: Dufies, Maeva, et al.
Publicado: (2017) -
Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-ΔC in clear cell Renal Cell Carcinoma patients
por: Fabbri, Lucilla, et al.
Publicado: (2020) -
Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
por: Montemagno, Christopher, et al.
Publicado: (2020) -
The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy
por: Hagege, Anais, et al.
Publicado: (2021)